The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of <i>EGFR</i> exon 20: A retrospective analysis.

Sci Prog · 2025 · PMC11924084 · PMID 40105649

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, compared to chemotherapy and traditional EGFR -TKIs, the improvement in mPFS for first-line ICI-combined regimen did not reach statistical significance, mainly due to the small sample size in the ICI-combined regimen group.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of &lt;i&gt;EGFR&lt;/i&gt; exon 20: A retrospective analysis.

The sentences

The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of <i>EGFR</i> exon 20: A retrospective analysis.